Pharma Could Face Fewer False Claims Act Suits If Supreme Court Concurs With Government
High court is to determine whether the government can dismiss an FCA complaint after initially declining to take it on. In recent years, the government has dismissed numerous qui tam suits against pharma companies in which it did not intervene.
You may also be interested in...
Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Cases
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.
Will US Government Pursue Fewer False Claims Act Cases In 2019?
Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.
False Claims Act: US Justice Department Gives Pharma Early Christmas Present
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.